2.66
-0.19 (-6.67%)
| Penutupan Terdahulu | 2.85 |
| Buka | 2.83 |
| Jumlah Dagangan | 964,488 |
| Purata Dagangan (3B) | 886,112 |
| Modal Pasaran | 96,401,064 |
| Harga / Jualan (P/S) | 255.50 |
| Harga / Buku (P/B) | 25.06 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| EPS Cair (TTM) | -0.830 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.50% |
| Nisbah Semasa (MRQ) | 2.22 |
| Aliran Tunai Operasi (OCF TTM) | -19.11 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.84 M |
| Pulangan Atas Aset (ROA TTM) | -97.10% |
| Pulangan Atas Ekuiti (ROE TTM) | -290.21% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Gain Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.50 |
|
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.78% |
| % Dimiliki oleh Institusi | 8.14% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 9.00 (BTIG, 238.35%) | Beli |
| Median | 8.00 (200.75%) | |
| Rendah | 7.00 (Maxim Group, 163.16%) | Beli |
| Purata | 8.00 (200.75%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 1.93 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 15 Oct 2025 | 9.00 (238.35%) | Beli | 1.87 |
| 08 Sep 2025 | 9.00 (238.35%) | Beli | 1.75 | |
| HC Wainwright & Co. | 13 Oct 2025 | 8.00 (200.75%) | Beli | 1.90 |
| Maxim Group | 07 Oct 2025 | 7.00 (163.16%) | Beli | 2.02 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Nov 2025 | Pengumuman | Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 |
| 12 Nov 2025 | Pengumuman | Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update |
| 30 Oct 2025 | Pengumuman | Gain Therapeutics to Present at Neuroscience 2025 |
| 16 Oct 2025 | Pengumuman | Gain Therapeutics to Attend the 2025 Maxim Growth Summit |
| 09 Oct 2025 | Pengumuman | Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease |
| 06 Oct 2025 | Pengumuman | Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders® |
| 23 Sep 2025 | Pengumuman | Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025 |
| 18 Sep 2025 | Pengumuman | Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |